Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Scientists provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer's disease. Their findings, based on studies in cell culture, mice and tissue ...

Scientists from DZNE, University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer's disease ...

Using a single-cell sequencing technique, Brazilian researchers have created the first cell atlas of focal cortical dysplasia ...

Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS MASITINIB PLATFORMParis, January 29, 2025, 7pm CETAB Science SA (Euronext - FR0010557264 - AB) ...

You may see a FaceTime or iMessage activation error like "iMessage waiting for activation" or "iMessage activation unsuccessful." If you get a FaceTime or iMessage ...

NEW YORK - Tiziana Life Sciences Ltd. (NASDAQ:TLSA), a biotech firm focused on immunomodulation therapies with a market capitalization of $87 million, has announced promising preclinical results for ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Our previous research demonstrates that the CD40 signaling is critically involved in microglia-related immune responses in the brain. For example, it is well known that the activation of the ...